Trial Profile

A Phase Ib Study of SHR-1316 in Combination With Fluzoparib SHR-3162 in Small Cell Lung Cancer Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; Fuzuloparib (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

16 Jun 2022 Status changed from recruiting to completed.
14 Sep 2021 Status changed from not yet recruiting to recruiting.
14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com